Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia
Andrea Ghelli Luserna di Rorà(Fondazione Pisa), Giovanni Martinelli(University of Bologna), Anna Ferrari(University of Bologna), Chiara Sartor(University of Bologna), Maria Chiara Fontana(Istituto Oncologico Romagnolo), Maria Chiara Abbenante(University of Bologna), Giovanni Marconi(University of Bologna), Chiara Ronchini(European Institute of Oncology), Sarah Parisi(University of Bologna), Cristina Papayannidis(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Neil Beeharry(Johnson & Johnson (United States)), Pier Giuseppe Pelicci(Office of Technology Transfer), Tim J. Yen(Fox Chase Cancer Center), Elena Sabattini(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Ilaria Iacobucci(St. Jude Children's Research Hospital), Nicoletta Testoni(Thrombolysis in Myocardial Infarction Study Group), Michèle Cavo(Unknown), Simona Righi(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Carmen Baldazzi(University of Bologna), Enrica Imbrogno(University of Bologna), Stefania Paolini(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Maria Vittoria Verga Falzacappa(University of Trieste), Valentina Robustelli(University of Bologna)
Cited by 56
Related Papers
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
|Nature reviews. Cancer|2006|2.2k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction
|Cell|1992|1.3k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k